Abstract
Osteoarthritis (OA) is a degenerative bone disease that results in inflammation of the joint cartilage. Approximately 58 million adults in the world are affected by this disease, which is characterized by pain, stiffness, and decrease in bone density. The current medication for the treatment of OA is non-steroidal anti-inflammatory drugs (NSAID), opioids, and cyclooxygenase (COX)-2-specific drugs which reduce the pain but do not improve the cartilage disorder. The marketed available drugs for the treatment of OA have gastrointestinal, cardiovascular, and addiction problems. To overcome the limitations of knee OA drug treatment, stem-cell-based therapy is being utilized to recover the knee from the pain and regenerate the cartilage from its recent damaged state. The objective of this study is to effectively manage osteoarthritis by Human Mesenchymal Stem Cell (hMSC) delivery to bone cartilage. In our study, OA in rat knees was produced by intra-articular papain enzyme injections and was observed by pain behavior assay. Latencies in rats treated by papain enzyme were significantly decreased compared to saline. We observed that female rats produced more arthritis by papain enzyme than male rats. The results of the hot plate test showed that the paw-withdrawal threshold was significantly decreased by stem cell administration. We found 52% response by von Frey test in enzyme treated with stem cell delivery osteoarthritis rats, whereas above 80% response was observed in only enzyme treated rats. In this study, we observed that stem cell delivery contributes to the suppression of cartilage degradation in rat knees. Our research demonstrates that stem cell therapy could be a promising treatment in terms of combating tissue regeneration of rat knees to improve the pain state in the target area.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call